Formats
  1. Journal Article (66746)
  2. Meeting Abstract (33620)
  3. Book Section (5027)
  4. Review (3744)
  5. Editorial (2162)
  6. Conference Paper (1525)
  7. Correspondence (661)
  8. Guidelines (660)
  9. Research Letter (548)
  10. Miscellaneous (339)
  11. Book Whole (338)
Groups
  1. Department of Medicine (39033)
  2. GSK Faculty (22468)
  3. Solid Tumor Oncology Division (22056)
  4. Surgery (21247)
  5. Sloan Kettering Institute Faculty (16086)
  6. Survivorship Research (15762)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1050)

More People

Years
  1. 2025 (1982)
  2. 2024 (5377)
  3. 2023 (5804)
  4. 2022 (6168)
  5. 2021 (5712)
  6. 2020 (5598)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4950)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2610)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1812)

More Publications

Publishers
  1. Elsevier Inc. (13855)
  2. American Society of Clinical Oncology (9157)
  3. Springer (7152)
  4. Nature Publishing Group (6367)
  5. American Association for Cancer Research (6002)
  6. Elsevier Science, Inc. (5503)

More Publishers

Results (115370)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Meeting Abstract

    Porta, C. G.; Burotto, M.; Suarez Rodriguez, C.; Bourlon, M. T.; Hsieh, J.; Shah, A. Y.; Hamzaj, A.; Bedke, J.; Pook, D.; Kessler, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • SAABR: Single arm phase II study of abiraterone + atezolizumab + GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)
    Meeting Abstract

    Rathkopf, D. E.; Decker, B.; Schum, P.; McBride, S.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • PSMAddition: A phase III trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Tagawa, S. T.; Sartor, O.; Saad, F.; Sakharova, O.; de Bono, J.; Feng, F.; Fizazi, K.; Morris, M. J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • PSMAfore: A phase III study to compare (177)Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naive patients with mCRPC
    Meeting Abstract

    Morris, M. J.; Sartor, O.; Chi, K. N.; de Bono, J. S.; Shore, N. D.; Crosby, M.; Dalal, D.; Fizazi, K.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
    Meeting Abstract

    Choueiri, T. K.; Eto, M.; Kopyltsov, E.; Rha, S. Y.; Porta, C. G.; Motzer, R.; Grünwald, V.; Hutson, T. E.; Méndez-Vidal, M. J.; Hong, S. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Conditional survival and 5-year follow-up in CheckMate 214: First-line nivolumab + ipilimumab (N+I) versus sunitinib (S) in advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Tannir, N. M.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C. G.; George, S.; Powles, T. B.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Safety of tazemetostat (TAZ) in combination with abiraterone/prednisone (A/P) or enzalutamide (E) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Iannotti, N.; Kocabas Argon, E.; Appleman, L.; Michaud, N.; Rajarethinam, A.; Adib, D.; Saltzstein, D. R.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Biochemical response (PSA0) and testosterone (T) recovery in Metacure, a multi-arm multi-modality (MM) therapy (tx) for very high risk localized (HRL) and low volume metastatic (LVM) prostatic adenocarcinoma
    Meeting Abstract

    Teo, M. Y.; McBride, S.; Gopalan, A.; Benoliel, H.; Eastham, J. A.; Goh, A.; Szmulewitz, R.; Morgans, A. K.; Bubley, G.; Gupta, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase Ib study of enzalutamide (Enza) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Zhao, J. L.; Antonarakis, S.; Cheng, H.; George, D. J.; Aggarwal, R. R.; Abida, W.; Decker, B.; Smart-Curley, T.; Schonhoft, J.; Anderson, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Keegan, N. M.; Schonhoft, J.; Barnett, E.; Cohn, E. D.; Zhao, J. L.; Carbone, E. A.; Zanone, M. R.; Anderson, A.; Wenstrup, R.; Scher, H. I.
    Annals of Oncology (2021)

    Fulltext@MSK | Save